Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aims to harness, direct and optimize their immune suppressive properties to address serious ...
CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of canc ...
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics ...
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating ...
GDAŃSK, Poland, March 10, 2026 (GLOBE NEWSWIRE) -- PolTREG SA (WSE: PTG), a pioneer and global leader in the development of therapies using T-regulatory lymphocytes (TREGs), announces that a ...
Terumo Blood and Cell Technologies has entered a new collaboration with Taiwan Bio Therapeutics to transition regulatory T‑cell manufacturing onto the automated Quantum Flex platform, marking a shift ...
Collaboration brings together Quell’s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca’s proven development and commercial capabilities as ...
Over four decades ago, a surprising observation hinted at a specialized T cell population capable of suppressing autoimmunity. Now known as regulatory T cells, or Tregs, these immune modulators are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results